• Celldex Therapeutics (NasdaqCM:CLDX) plans to present new clinical results for barzolvolimab in chronic and cold urticaria at the 2026 European Academy of Allergy and Clinical Immunology Congress.
• The company will also share first in human Phase 1 data for CDX-622, targeting KIT signaling in mast cells.
• These data represent fresh updates on Celldex’s core pipeline that have not been covered in earlier reports.

Celldex enters this data update with its stock at $29.96 and a return of 47.2% over the past year, while the 3 year return is down 18.7% and the 5 year return is 7.0%. That mix of outcomes provides context for how investors may weigh new clinical readouts on barzolvolimab and CDX-622, both key programs for the company.

For investors, the upcoming congress matters because it concentrates fresh, externally reviewed information into a single event. The barzolvolimab and CDX-622 presentations could clarify how Celldex’s pipeline is progressing in mast cell driven diseases and help investors assess whether the current risk and reward profile of NasdaqCM:CLDX aligns with their portfolio approach.

Stay updated on the most important news stories for Celldex Therapeutics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Celldex Therapeutics.

The planned data presentations put Celldex’s focus on mast cell driven diseases in front of a specialist audience that closely follows allergy and immunology drugs. Barzolvolimab in chronic spontaneous urticaria and cold urticaria sits in a space where larger companies such as Novartis and Sanofi already market therapies, so fresh clinical details on efficacy, durability of response, and safety will help investors judge whether Celldex is building a differentiated profile. CDX-622, which targets KIT signaling in mast cells, broadens the company’s toolkit against mast cell biology and could point to future indications beyond urticaria. For a business that reported only US$865,000 in revenue and a net loss of US$283.646m, clearer visibility on potential future products and addressable patient populations is central to any long-term equity story. The 47.2% one year share price return, alongside weaker 3 year and 5 year returns, suggests the market already reacts strongly to clinical news, so the quality and depth of these 2026 congress data will likely be an important reference point for both existing and prospective shareholders.

The Risks and Rewards Investors Should Consider

• ⚠️ Celldex is currently unprofitable and is not forecast to reach profitability over the next 3 years, so progress depends heavily on external funding and capital markets access.
• ⚠️ The company makes less than US$1m in revenue and shareholders have experienced dilution over the past year, which may concern investors who are sensitive to funding risk.
• 🎁 Revenue is forecast to grow 66.88% per year, so successful development of barzolvolimab and CDX-622 could have a meaningful impact on future sales potential.
• 🎁 The stock is trading at 64.6% below one estimate of its fair value, and new data on core pipeline assets may help investors reassess how they value Celldex’s longer term prospects.

What To Watch Going Forward

After the 2026 European Academy of Allergy and Clinical Immunology Congress, focus on the detailed barzolvolimab results in chronic spontaneous urticaria and cold urticaria, including how they compare with existing treatments from larger players such as Novartis and Sanofi. For CDX-622, pay attention to safety, target engagement, and any early signals that KIT inhibition in mast cells could translate into broader indications. Funding and dilution remain key watchpoints, so track how Celldex manages its cash position while advancing multiple trials. Given the mixed share price record over 3 and 5 years, monitor how the market reacts to these readouts and whether management outlines clear next steps in study design, regulatory interactions, and potential partnering discussions.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Celldex Therapeutics, head to the community page for Celldex Therapeutics to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.